2. Academic Validation
  3. Mutations in ADAR1, IFIH1, and RNASEH2B presenting as spastic paraplegia

Mutations in ADAR1, IFIH1, and RNASEH2B presenting as spastic paraplegia

  • Neuropediatrics. 2014 Dec;45(6):386-93. doi: 10.1055/s-0034-1389161.
Yanick J Crow 1,  Maha S Zaki 2,  Mohamed S Abdel-Hamid 3,  Ghada Abdel-Salam 2,  Odile Boespflug-Tanguy 4,  Nuno J V Cordeiro 5,  Joseph G Gleeson 6,  Nirmala Rani Gowrinathan 7,  Vincent Laugel 8,  Florence Renaldo 9,  Diana Rodriguez 10,  John H Livingston 11,  Gillian I Rice 12
Affiliations

Affiliations

  • 1 INSERM UMR 1163, Laboratory of Neurogenetics and Neuroinflammation, Institut Imagine, Paris, France.
  • 2 Division of Human Genetics and Genome Research, Department of Clinical Genetics, National Research Center, Cairo, Egypt.
  • 3 Division of Human Genetics and Genome Research, Department of Medical Genetics, National Research Center, Cairo, Egypt.
  • 4 National Reference Center for Rare Diseases "leukodystrophies," INSERM U676, Université Paris Diderot, Sorbonne Paris Cité Université, Paris, France.
  • 5 Department of Paediatrics, Rainbow House NHS Ayrshire & Arran, Irvine, Scotland, United Kingdom.
  • 6 Department of Neurosciences, University of California, San Diego, La Jolla, California, United States.
  • 7 Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States.
  • 8 Pediatric Neurology, Strasbourg-Hautepierre University Hospital, Avenue Moliere, Strasbourg, France.
  • 9 Centre de Référence des Leucodystrophies, Service de Neuropédiatrie et Maladies Métaboliques; Hôpital Robert Debré, AP-HP, Paris, France.
  • 10 Service de Neuropédiatrie, Hôpital Armand Trousseau, Paris, France.
  • 11 Department of Paediatric Neurology, F Floor Martin Wing, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom.
  • 12 Manchester Academic Health Science Centre, University of Manchester, Genetic Medicine, Manchester, United Kingdom.
PMID: 25243380 DOI: 10.1055/s-0034-1389161
Abstract

Background: Hereditary spastic paraplegia is a neurodegenerative phenotype characterized by a progressive loss of corticospinal motor tract function. In a majority of affected individuals the pathogenesis remains undetermined.

Methods: We identified a series of patients with a phenotype of nonsyndromic spastic paraplegia in whom no diagnosis had been reached before exome sequencing. We measured the expression of interferon stimulated genes (ISGs) in peripheral blood from these patients.

Results: Five patients from four families with previously unexplained spastic paraplegia were identified with mutations in either ADAR1 (one patient), IFIH1 (one patient), or RNASEH2B (three patients from two families). All patients were developmentally normal before the onset of features beginning in the second year of life. All patients remain of normal intellect. Four patients demonstrated normal neuroimaging, while a single patient had features of nonspecific dysmyelination. The patients with ADAR1 and IFIH1-related disease showed a robust interferon signature. The patients with mutations in RNASEH2B demonstrated no (two patients) or a minimal (one patient) upregulation of ISGs compared with controls.

Conclusions: Mutations in ADAR1, IFIH1, and RNASEH2B can cause a phenotype of spastic paraplegia with normal neuroimaging, or in association with nonspecific dysmyelination. Although the presence of an interferon signature can be helpful in interpreting the significance of gene variants in this context, patients with pathogenic mutations in RNASEH2B may demonstrate no upregulation of ISGs in peripheral blood. However, it remains possible that type I interferons act as a neurotoxin in the context of all genotypes.

Figures